Relmada Therapeutics, Inc.
RLMD
$7.49
$0.040.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 51.82% | -46.95% | -8.59% | -35.27% | -33.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.59% | -55.12% | -45.69% | -20.75% | -28.90% |
| Operating Income | -6.59% | 55.12% | 45.69% | 20.75% | 28.90% |
| Income Before Tax | -6.49% | 53.55% | 44.47% | 19.56% | 25.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.49% | 53.55% | 44.47% | 19.56% | 25.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.49% | 53.55% | 44.47% | 19.56% | 25.86% |
| EBIT | -6.59% | 55.12% | 45.69% | 20.75% | 28.90% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 47.40% | 57.78% | 49.52% | 20.29% | 26.05% |
| Normalized Basic EPS | 46.54% | 58.63% | 49.59% | 19.67% | 28.14% |
| EPS Diluted | 47.40% | 57.78% | 49.52% | 20.29% | 26.05% |
| Normalized Diluted EPS | 46.54% | 58.63% | 49.59% | 19.67% | 28.14% |
| Average Basic Shares Outstanding | 102.48% | 10.00% | 10.00% | 0.92% | 0.25% |
| Average Diluted Shares Outstanding | 102.48% | 10.00% | 10.00% | 0.92% | 0.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |